Alisa Jennifer Prager, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glaucoma | 7 | 2022 | 1159 | 1.280 |
Why?
|
Visual Fields | 3 | 2021 | 1047 | 0.940 |
Why?
|
Visual Field Tests | 3 | 2021 | 383 | 0.820 |
Why?
|
Neurocutaneous Syndromes | 1 | 2021 | 51 | 0.740 |
Why?
|
Arteriovenous Fistula | 1 | 2021 | 315 | 0.610 |
Why?
|
Tomography, Optical Coherence | 3 | 2022 | 2657 | 0.590 |
Why?
|
Eye Diseases | 2 | 2022 | 669 | 0.590 |
Why?
|
Fluorescein Angiography | 1 | 2021 | 940 | 0.560 |
Why?
|
Macula Lutea | 1 | 2017 | 151 | 0.550 |
Why?
|
Retinal Vessels | 1 | 2021 | 772 | 0.520 |
Why?
|
Glaucoma, Open-Angle | 1 | 2021 | 706 | 0.490 |
Why?
|
Vision Disorders | 1 | 2021 | 1058 | 0.460 |
Why?
|
Retinal Ganglion Cells | 1 | 2017 | 770 | 0.400 |
Why?
|
Visual Acuity | 2 | 2017 | 2530 | 0.400 |
Why?
|
Disease Management | 1 | 2021 | 2459 | 0.360 |
Why?
|
Medicare | 2 | 2018 | 6566 | 0.340 |
Why?
|
Brain Diseases | 1 | 2015 | 1563 | 0.260 |
Why?
|
Self Report | 1 | 2016 | 3558 | 0.250 |
Why?
|
Health Care Costs | 1 | 2016 | 3209 | 0.210 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3022 | 0.210 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 35421 | 0.210 |
Why?
|
Hospitalization | 2 | 2018 | 10262 | 0.200 |
Why?
|
Medicare Part D | 2 | 2016 | 328 | 0.190 |
Why?
|
Brain Neoplasms | 4 | 2015 | 8863 | 0.190 |
Why?
|
beta-Alanine | 1 | 2021 | 74 | 0.190 |
Why?
|
Quality of Life | 4 | 2022 | 12804 | 0.190 |
Why?
|
Ocular Hypertension | 1 | 2022 | 198 | 0.180 |
Why?
|
Blastomycosis | 1 | 2019 | 16 | 0.180 |
Why?
|
Fundus Oculi | 1 | 2021 | 473 | 0.180 |
Why?
|
Glioma | 1 | 2015 | 3401 | 0.180 |
Why?
|
Benzoates | 1 | 2021 | 217 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2015 | 9239 | 0.170 |
Why?
|
Dacryocystitis | 1 | 2019 | 70 | 0.170 |
Why?
|
Scotoma | 1 | 2017 | 139 | 0.140 |
Why?
|
Health Plan Implementation | 2 | 2016 | 352 | 0.130 |
Why?
|
Vision, Binocular | 1 | 2017 | 213 | 0.130 |
Why?
|
Disease Progression | 3 | 2022 | 13284 | 0.120 |
Why?
|
Hepatocyte Growth Factor | 1 | 2013 | 270 | 0.110 |
Why?
|
Osteopontin | 1 | 2013 | 296 | 0.100 |
Why?
|
Dacarbazine | 1 | 2015 | 566 | 0.100 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 424 | 0.100 |
Why?
|
Drug Costs | 2 | 2016 | 1105 | 0.100 |
Why?
|
Health Services Research | 1 | 2018 | 1836 | 0.100 |
Why?
|
Prostatic Neoplasms | 1 | 2013 | 11124 | 0.090 |
Why?
|
Confidence Intervals | 1 | 2016 | 2971 | 0.090 |
Why?
|
Cost Savings | 1 | 2015 | 926 | 0.090 |
Why?
|
Cross-Sectional Studies | 4 | 2018 | 25043 | 0.090 |
Why?
|
Brain Stem Neoplasms | 1 | 2011 | 204 | 0.090 |
Why?
|
Area Under Curve | 1 | 2013 | 1654 | 0.090 |
Why?
|
Antihypertensive Agents | 2 | 2016 | 2046 | 0.090 |
Why?
|
Metabolic Networks and Pathways | 1 | 2013 | 783 | 0.080 |
Why?
|
Prescription Drugs | 1 | 2016 | 595 | 0.080 |
Why?
|
Ophthalmic Solutions | 2 | 2022 | 317 | 0.080 |
Why?
|
Aged | 10 | 2018 | 163280 | 0.080 |
Why?
|
Glioblastoma | 2 | 2013 | 3481 | 0.080 |
Why?
|
Radiotherapy | 1 | 2015 | 1533 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2021 | 2214 | 0.080 |
Why?
|
Humans | 20 | 2022 | 744343 | 0.080 |
Why?
|
Interferon-alpha | 1 | 2011 | 895 | 0.070 |
Why?
|
Kidney Transplantation | 1 | 2022 | 4251 | 0.070 |
Why?
|
Female | 15 | 2021 | 380194 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3870 | 0.070 |
Why?
|
Molecular Imaging | 1 | 2013 | 828 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2011 | 1182 | 0.070 |
Why?
|
ROC Curve | 1 | 2013 | 3527 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2013 | 1180 | 0.070 |
Why?
|
Male | 14 | 2018 | 350118 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12959 | 0.070 |
Why?
|
Insurance Coverage | 1 | 2016 | 1901 | 0.060 |
Why?
|
Comorbidity | 1 | 2018 | 10388 | 0.060 |
Why?
|
Medication Adherence | 1 | 2015 | 2063 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5751 | 0.060 |
Why?
|
Prostate-Specific Antigen | 1 | 2013 | 2494 | 0.060 |
Why?
|
Neurosurgical Procedures | 1 | 2015 | 2002 | 0.060 |
Why?
|
Radiosurgery | 1 | 2013 | 1329 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2018 | 57776 | 0.060 |
Why?
|
Databases, Factual | 1 | 2018 | 7729 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9849 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2016 | 13989 | 0.060 |
Why?
|
Middle Aged | 6 | 2021 | 213383 | 0.050 |
Why?
|
United States | 4 | 2018 | 69872 | 0.050 |
Why?
|
Hypertension | 1 | 2022 | 8480 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7785 | 0.050 |
Why?
|
Retrospective Studies | 3 | 2022 | 77449 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2013 | 14722 | 0.050 |
Why?
|
Logistic Models | 1 | 2016 | 13408 | 0.050 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2012 | 2737 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2015 | 13695 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2013 | 11031 | 0.040 |
Why?
|
Electromagnetic Fields | 1 | 2000 | 298 | 0.040 |
Why?
|
Incidence | 1 | 2016 | 20947 | 0.040 |
Why?
|
Prognosis | 2 | 2013 | 29063 | 0.030 |
Why?
|
Intraocular Pressure | 1 | 2022 | 1270 | 0.030 |
Why?
|
Sickness Impact Profile | 1 | 2017 | 302 | 0.030 |
Why?
|
Prospective Studies | 2 | 2017 | 53288 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2012 | 9274 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2017 | 39050 | 0.030 |
Why?
|
Risk Assessment | 1 | 2016 | 23338 | 0.030 |
Why?
|
Cysts | 1 | 2019 | 678 | 0.030 |
Why?
|
Financing, Personal | 1 | 2016 | 308 | 0.030 |
Why?
|
Visual Cortex | 1 | 2000 | 1149 | 0.030 |
Why?
|
Graft Rejection | 1 | 2022 | 4397 | 0.020 |
Why?
|
Drug Utilization | 1 | 2015 | 1183 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2013 | 2327 | 0.020 |
Why?
|
Necrosis | 1 | 2013 | 1643 | 0.020 |
Why?
|
Gene Amplification | 1 | 2013 | 1063 | 0.020 |
Why?
|
Income | 1 | 2016 | 1913 | 0.020 |
Why?
|
Brain | 1 | 2013 | 26385 | 0.020 |
Why?
|
Preoperative Care | 1 | 2013 | 2250 | 0.010 |
Why?
|
Up-Regulation | 1 | 2013 | 4217 | 0.010 |
Why?
|
Lacrimal Apparatus | 1 | 1966 | 225 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 4933 | 0.010 |
Why?
|
Health Expenditures | 1 | 2016 | 2348 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6622 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2011 | 6895 | 0.010 |
Why?
|
Phosphenes | 1 | 2000 | 44 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2011 | 8642 | 0.010 |
Why?
|
Sensory Thresholds | 1 | 2000 | 391 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2000 | 876 | 0.010 |
Why?
|
Adolescent | 3 | 2013 | 85781 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 19905 | 0.010 |
Why?
|
Electromyography | 1 | 2000 | 1379 | 0.010 |
Why?
|
Electric Stimulation | 1 | 2000 | 1767 | 0.010 |
Why?
|
Reference Values | 1 | 2000 | 4982 | 0.010 |
Why?
|
Adult | 4 | 2013 | 214055 | 0.010 |
Why?
|
Motor Cortex | 1 | 2000 | 986 | 0.010 |
Why?
|
Infant | 2 | 2011 | 35136 | 0.010 |
Why?
|
Child, Preschool | 2 | 2011 | 41006 | 0.010 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2000 | 1432 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13102 | 0.010 |
Why?
|
Young Adult | 1 | 2013 | 56430 | 0.000 |
Why?
|
Aging | 1 | 1966 | 8664 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2013 | 20822 | 0.000 |
Why?
|
Child | 2 | 2011 | 77709 | 0.000 |
Why?
|
Conjunctivitis | 1 | 1966 | 158 | 0.000 |
Why?
|
Atrophy | 1 | 1966 | 1583 | 0.000 |
Why?
|